By Sneha S K (Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Pfizer's marstacimab (Hympavzi), an IgG1 monoclonal antibody that helps promote clotting, remains on the market. The drug was ...

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Sensorion's Audiogene Phase I/II trial of the SENS-501 gene therapy programme has received a favourable recommendation from ...

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

MeiraGTx’s investigational gene therapy AAV-AIPL1 has improved the sight of 11 children who were born blind. MeiraGTx is ...

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

Revolutionary gene therapy approaches show promise in treating various retinal conditions, potentially transforming treatment ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

In recent weeks, Children’s Hospital Los Angeles in East Hollywood has taken steps to improve care for some of its pediatric patients. In late January, ...

A groundbreaking gene therapy has restored sight in four young children born with severe blindness due to a rare genetic ...